CLBT
Cellebrite Di Ltd. Information Technology Services-Prepackaged Software Russell 3000
$12.15Close
$3.0BMarket cap
$10.44 – $19.2852-week range
Nov 12, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 16 · weaker than 84% of stocks over 12 months
- Far from its high 37% below its 52-week high
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
37%
1wk
up 0.4%
price change
1mo
up 7.9%
price change
12-month return
down 29%
market up 11% ·
its own down 41%
F-score
5 / 9
Mixed
Altman Z″
2.73
Low risk
P/E
38.6×
price / earnings
PEG
—
P/E / EPS growth
P/B
6.2×
price / book
Earnings yield
up 2.3%
EBIT / enterprise value
Cheaper than
45%
of the market · around average
Revenue growth
up 19%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
up 19%
return on equity
Free cash margin
up 34%
$160.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.6×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
3.5%
$0.42 a day · 2×ATR $11.31
RS
16 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.78
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 1 of 8
- Price above the 50-day average: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 6.0% over the year, from 235m to 249m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last shock
Aug 13, 2026-29% in one session15.4× volumeno filing matched+12% since
Financials
- Gross 84%
- Net 16%
- Free cash 34%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $194.9M | $246.2M | $270.7M | $325.1M | $401.2M | $475.7M |
| Gross margin | 81% | 83% | 81% | 84% | 84% | 84% |
| Operating income | $9.2M | $13.8M | $1.0M | $33.2M | $56.9M | $66.5M |
| Net income | $5.8M | $71.4M | $120.8M | -$81.1M | -$283.0M | $78.3M |
| Net margin | 3% | 29% | 45% | -25% | -71% | 16% |
| Earnings per share | $0.04 | $0.42 | $0.59 | -$0.43 | -$1.35 | $0.31 |
| Free cash flow | $60.3M | $30.9M | $13.7M | $96.8M | $123.6M | $160.3M |
| Free cash margin | 31% | 13% | 5% | 30% | 31% | 34% |
| Cash | $133.8M | $146.0M | $87.6M | $189.5M | $191.7M | $124.5M |
| Shareholders' equity | $63.8M | -$73.3M | $73.9M | $34.2M | $336.0M | $484.3M |
| Shares outstanding | 129.93m | 195.60m | 201.16m | 211.81m | 234.52m | 248.58m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Aug 14, 2025 | Interim ↗ | Jun 30, 2025 | 45d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Aug 15, 2024 | Interim ↗ | Jun 30, 2024 | 46d |
| Mar 21, 2024 | Annual ↗ | Dec 31, 2023 | 81d |
| Sep 1, 2023 | Interim ↗ | Jun 30, 2023 | 63d |
| Apr 27, 2023 | Annual ↗ | Dec 31, 2022 | 117d |
| Sep 13, 2022 | Interim ↗ | Jun 30, 2022 | 75d |
| Mar 29, 2022 | Annual ↗ | Dec 31, 2021 | 88d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 24, 2026 | Foreign issuer report ↗ |
| Sep 2, 2026 | Foreign issuer report ↗ |
| Aug 18, 2026 | Foreign issuer report ↗ |
| Aug 13, 2026 | Foreign issuer report ↗ |
| Aug 13, 2026 | Foreign issuer report ↗ |
| Aug 13, 2026 | Foreign issuer report ↗ |
| May 14, 2026 | Foreign issuer report ↗ |
| Feb 11, 2026 | Foreign issuer report ↗ |
| Dec 2, 2025 | Foreign issuer report ↗ |
| Nov 12, 2025 | Foreign issuer report ↗ |
| Sep 22, 2025 | Foreign issuer report ↗ |
| Aug 15, 2025 | Foreign issuer report ↗ |